P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial

Severine Vermeire; Bruce E. Sands; M. Dubinsky; Brian G. Feagan; Remo Panaccione; Vipul Jairath; A. Yarur; Michael V. Chiorean; Julian Panes; M. Goetsch; C.J. Rabbat; P. Shah; J. Wu; Subrata Ghosh

doi:10.1093/ecco-jcc/jjac190.0712

P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial

Severine Vermeire
, Bruce E. Sands
, M. Dubinsky
, Brian G. Feagan
, Remo Panaccione
, Vipul Jairath
, A. Yarur
, Michael V. Chiorean
, Julian Panes
, M. Goetsch
, C.J. Rabbat
, P. Shah
, J. Wu
, Subrata Ghosh

KU Leuven
Icahn School of Medicine at Mount Sinai
Western University
University of Calgary
Cedars-Sinai Medical Center
Inflammatory Bowel Disease Center
Hospital Clínic de Barcelona
Pfizer
Pfizer

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of ulcerative colitis (UC). The ELEVATE UC 52 trial utilized a treat-through design which evaluated efficacy at week 52 among all subjects randomised from baseline. Here, we report a post hoc analysis of efficacy at week 52 among subjects who did or did not achieve clinical response at the end of the 12-week induction period in ELEVATE UC 52.

Original language	English
Journal	Journal of Crohn's and Colitis
Volume	17
Issue number	1
DOIs	https://doi.org/10.1093/ecco-jcc/jjac190.0712
Publication status	Published - 30 Jan 2023
Event	18th Congress of ECCO Copenhagen - Copenhagen, Denmark Duration: 1 Mar 2023 → 4 Mar 2023

Keywords

Medicine
Post-hoc analysis
Post hoc
Internal medicine
Clinical trial
Placebo
Gastroenterology
Clinical endpoint
Ulcerative colitis
Disease
Alternative medicine
Pathology

Access to Document

10.1093/ecco-jcc/jjac190.0712Licence: Unspecified

Cite this

Vermeire, S., Sands, B. E., Dubinsky, M., Feagan, B. G., Panaccione, R., Jairath, V., Yarur, A., Chiorean, M. V., Panes, J., Goetsch, M., Rabbat, C. J., Shah, P., Wu, J., & Ghosh, S. (2023). P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial. Journal of Crohn's and Colitis, 17(1). https://doi.org/10.1093/ecco-jcc/jjac190.0712

@article{4ece94e64d714ee98db7835bf9d92f47,

title = "P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial",

abstract = "Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of ulcerative colitis (UC). The ELEVATE UC 52 trial utilized a treat-through design which evaluated efficacy at week 52 among all subjects randomised from baseline. Here, we report a post hoc analysis of efficacy at week 52 among subjects who did or did not achieve clinical response at the end of the 12-week induction period in ELEVATE UC 52.",

keywords = "Medicine, Post-hoc analysis, Post hoc, Internal medicine, Clinical trial, Placebo, Gastroenterology, Clinical endpoint, Ulcerative colitis, Disease, Alternative medicine, Pathology",

author = "Severine Vermeire and Sands, \{Bruce E.\} and M. Dubinsky and Feagan, \{Brian G.\} and Remo Panaccione and Vipul Jairath and A. Yarur and Chiorean, \{Michael V.\} and Julian Panes and M. Goetsch and C.J. Rabbat and P. Shah and J. Wu and Subrata Ghosh",

year = "2023",

month = jan,

day = "30",

doi = "10.1093/ecco-jcc/jjac190.0712",

language = "English",

volume = "17",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "1",

note = "18th Congress of ECCO Copenhagen ; Conference date: 01-03-2023 Through 04-03-2023",

}

Vermeire, S, Sands, BE, Dubinsky, M, Feagan, BG, Panaccione, R, Jairath, V, Yarur, A, Chiorean, MV, Panes, J, Goetsch, M, Rabbat, CJ, Shah, P, Wu, J & Ghosh, S 2023, 'P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial', Journal of Crohn's and Colitis, vol. 17, no. 1. https://doi.org/10.1093/ecco-jcc/jjac190.0712

TY - JOUR

T1 - P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial

AU - Vermeire, Severine

AU - Sands, Bruce E.

AU - Dubinsky, M.

AU - Feagan, Brian G.

AU - Panaccione, Remo

AU - Jairath, Vipul

AU - Yarur, A.

AU - Chiorean, Michael V.

AU - Panes, Julian

AU - Goetsch, M.

AU - Rabbat, C.J.

AU - Shah, P.

AU - Wu, J.

AU - Ghosh, Subrata

PY - 2023/1/30

Y1 - 2023/1/30

N2 - Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of ulcerative colitis (UC). The ELEVATE UC 52 trial utilized a treat-through design which evaluated efficacy at week 52 among all subjects randomised from baseline. Here, we report a post hoc analysis of efficacy at week 52 among subjects who did or did not achieve clinical response at the end of the 12-week induction period in ELEVATE UC 52.

AB - Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of ulcerative colitis (UC). The ELEVATE UC 52 trial utilized a treat-through design which evaluated efficacy at week 52 among all subjects randomised from baseline. Here, we report a post hoc analysis of efficacy at week 52 among subjects who did or did not achieve clinical response at the end of the 12-week induction period in ELEVATE UC 52.

KW - Medicine

KW - Post-hoc analysis

KW - Post hoc

KW - Internal medicine

KW - Clinical trial

KW - Placebo

KW - Gastroenterology

KW - Clinical endpoint

KW - Ulcerative colitis

KW - Disease

KW - Alternative medicine

KW - Pathology

UR - https://openalex.org/W4318539746

U2 - 10.1093/ecco-jcc/jjac190.0712

DO - 10.1093/ecco-jcc/jjac190.0712

M3 - Meeting abstract

SN - 1873-9946

VL - 17

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

IS - 1

T2 - 18th Congress of ECCO Copenhagen

Y2 - 1 March 2023 through 4 March 2023

ER -

P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this